Endocrine therapies are highly effective in the initial stage of hormone-driven cancers treatment by targeting hormone receptor pathways; nevertheless, the development of resistance overtime has greatly impeded their long-term positive outcome, which is a key hindrance to effective cancer management [5,6]. Here, NR4A1 is linked to cancer.